The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1366
ISSUE1366
June 13, 2011
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
June 13, 2011 (Issue: 1366)
The FDA has approved Nuedexta (Avanir), a fixed-dose
combination of the cough suppressant dextromethorphan
hydrobromide and the antiarrhythmic
quinidine sulfate, for oral treatment of pseudobulbar
affect. The combination is the first treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.